• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.

作者信息

Ishani Areef, Guo Haifeng, Arneson Thomas J, Gilbertson David T, Mau Lih-Wen, Li Suying, Dunning Stephan, Collins Allan J

机构信息

Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S-406, Minneapolis, MN 55404, USA.

出版信息

J Am Soc Nephrol. 2009 Jul;20(7):1607-13. doi: 10.1681/ASN.2008080853. Epub 2009 Apr 23.

DOI:10.1681/ASN.2008080853
PMID:19389846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2709674/
Abstract
摘要

相似文献

1
Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.新的医疗保险报销政策对患有终末期肾病的非裔美国人可能产生的影响。
J Am Soc Nephrol. 2009 Jul;20(7):1607-13. doi: 10.1681/ASN.2008080853. Epub 2009 Apr 23.
2
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.美国慢性透析患者在医疗保险终末期肾病（ESRD）报销系统及促红细胞生成素（ESA）标签变更期间的红细胞（RBC）输血率。
BMC Nephrol. 2014 Jul 11;15:116. doi: 10.1186/1471-2369-15-116.
3
Bundled payment for ESRD--including ESAs in Medicare's dialysis package.终末期肾病的捆绑支付——医疗保险透析套餐中包括促红细胞生成素类似物。
N Engl J Med. 2011 Feb 17;364(7):593-5. doi: 10.1056/NEJMp1014187.
4
Toward Antiracist Reimbursement Policy in End-Stage Kidney Disease: From Equality to Equity.迈向终末期肾病的反种族主义报销政策：从平等到公平
J Am Soc Nephrol. 2021 Oct;32(10):2422-2424. doi: 10.1681/ASN.2021020189. Epub 2021 Jul 12.
5
Is it time for Medicare to provide reimbursement for daily hemodialysis?医疗保险是否该为每日血液透析提供报销了？
Nephrol News Issues. 2001 Apr;15(5):57-9.
6
Challenges and directions for Medicare ESRD payment policy.医疗保险终末期肾病支付政策面临的挑战与方向。
Semin Nephrol. 2000 Nov;20(6):565-76.
7
The Medicare end-stage renal disease program. A report from the Institute of Medicine.医疗保险终末期肾病项目。医学研究所的一份报告。
N Engl J Med. 1991 Apr 18;324(16):1143-8. doi: 10.1056/nejm199104183241628.
8
Medicare Enrollment Among Patients With End-Stage Kidney Disease Receiving Dialysis in Outpatient Facilities Between 2005 and 2016.2005 年至 2016 年间，在门诊接受透析治疗的终末期肾病患者的医疗保险参保情况。
JAMA. 2020 Apr 7;323(13):1314-1316. doi: 10.1001/jama.2020.0704.
9
Anemia: dialysis patients experiences.贫血：透析患者的经历。
Nephrol News Issues. 2004 Nov;18(12):49-54.
10
Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy.种族/民族和性别在促红细胞生成素刺激剂和输血使用方面的差异：医疗保险报销政策下的癌症管理。
J Manag Care Spec Pharm. 2020 Nov;26(11):1477-1486. doi: 10.18553/jmcp.2020.26.11.1477.

引用本文的文献

1
Insights into non-coding RNAS: biogenesis, function and their potential regulatory roles in acute kidney disease and chronic kidney disease.非编码RNA研究进展：生物合成、功能及其在急性肾损伤和慢性肾脏病中的潜在调控作用
Mol Cell Biochem. 2025 Mar;480(3):1287-1304. doi: 10.1007/s11010-024-05083-0. Epub 2024 Aug 7.
2
The economic considerations of patients and caregivers in choice of dialysis modality.患者及照护者在选择透析方式时的经济考量
Hemodial Int. 2016 Oct;20(4):634-642. doi: 10.1111/hdi.12424. Epub 2016 May 15.
3
Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.前瞻性支付系统实施后治疗实践和临床结果的比较变化：STEPPS研究
BMC Nephrol. 2015 May 1;16:67. doi: 10.1186/s12882-015-0059-8.
4
Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management?透析支付改革是否导致了贫血和矿物质代谢管理方面最初的种族差异？
J Am Soc Nephrol. 2015 Mar;26(3):754-64. doi: 10.1681/ASN.2013111232. Epub 2014 Oct 9.
5
Variation in dialysis quality measures by facility, neighborhood, and region.透析质量测量指标在医疗机构、社区和地区之间的差异。
Med Care. 2013 May;51(5):413-7. doi: 10.1097/MLR.0b013e318287d720.
6
An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.培格司亭用于慢性血液透析患者贫血维持治疗的开放性、序贯、剂量发现研究。
BMC Nephrol. 2012 Aug 30;13:95. doi: 10.1186/1471-2369-13-95.
7
Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients.变异血红蛋白表型可能导致非裔美国人血液透析患者中红细胞生成刺激剂的剂量存在差异。
Kidney Int. 2011 Nov;80(9):992-999. doi: 10.1038/ki.2011.247. Epub 2011 Aug 17.
8
Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year.在开始血液透析时达到 KDOQI 指南目标并在第一年期间生存。
Clin J Am Soc Nephrol. 2010 Sep;5(9):1574-81. doi: 10.2215/CJN.01320210. Epub 2010 Jun 10.

本文引用的文献

1
The association of race with erythropoietin dose in patients on long-term hemodialysis.长期血液透析患者种族与促红细胞生成素剂量的关联。
Am J Kidney Dis. 2008 Dec;52(6):1104-14. doi: 10.1053/j.ajkd.2008.07.026. Epub 2008 Sep 27.
2
The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.贫血管理在改善非裔美国慢性肾病患者预后方面的作用。
Am J Nephrol. 2008;28(5):732-43. doi: 10.1159/000127981. Epub 2008 Apr 24.
3
Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy.开始接受肾脏替代治疗的患者中种族和民族与贫血管理的关联。
J Natl Med Assoc. 2007 Nov;99(11):1218-26.
4
Laboratory abnormalities at the onset of treatment of end-stage renal disease: are there racial or socioeconomic disparities in care?终末期肾病治疗开始时的实验室异常情况：医疗护理中是否存在种族或社会经济差异？
Arch Intern Med. 2007 May 28;167(10):1083-91. doi: 10.1001/archinte.167.10.1083.
5
Correction of anemia with epoetin alfa in chronic kidney disease.慢性肾脏病中使用促红细胞生成素α纠正贫血
N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485.
6
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.慢性肾脏病合并贫血患者血红蛋白水平的正常化。
N Engl J Med. 2006 Nov 16;355(20):2071-84. doi: 10.1056/NEJMoa062276.
7
Resolving the paradigm crisis in intravenous iron and erythropoietin management.解决静脉铁剂和促红细胞生成素管理中的范式危机。
Kidney Int Suppl. 2006 May(101):S13-8. doi: 10.1038/sj.ki.5000405.
8
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.《慢性肾脏病贫血的改善全球肾脏病预后组织临床实践指南及临床实践建议》
Am J Kidney Dis. 2006 May;47(5 Suppl 3):S11-145. doi: 10.1053/j.ajkd.2006.03.010.
9
Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients.初发终末期肾病患者中心血管疾病患病率的种族差异。
Nephrol Dial Transplant. 2006 Aug;21(8):2202-9. doi: 10.1093/ndt/gfl078. Epub 2006 Mar 7.
10
Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking.慢性肾脏病患者对促红细胞生成素α的红细胞生成反应的种族差异及吸烟的影响
Nephrol Dial Transplant. 2005 Dec;20(12):2739-45. doi: 10.1093/ndt/gfi128. Epub 2005 Sep 27.